Improved anticancer efficiency of Mitoxantrone by Curcumin loaded PLGA nanoparticles targeted with AS۱۴۱۱ aptamer

سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 346

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_NAMJ-8-1_003

تاریخ نمایه سازی: 6 اردیبهشت 1400

چکیده مقاله:

Objective(s): Mitoxantrone (MTX) is one of the most commonly used chemotherapeutic agents for treatment of different cancers. However, prolonged treatment with MTX results in unwanted side effects and drug resistant cancer cells. Combination therapies and exploiting of targeted nanoparticles have the potential of improving the efficiency of drug treatment as well as reducing the side effects. Curcumin (CUR) is a biological molecules with anticancer property. In this study, we investigated whether targeted PLGA (Poly Lactic-co-Glycolic Acid)–CUR nanoparticles (NPs) can reinforce the effect of MTX on breast cancer cells.Materials and Methods: PLGA NPs containing CUR targeted with AS۱۴۱۱ aptamer were prepared by single emulsion evaporation method. Physicochemical properties of NPs were investigated. The cytotoxicity of non-targeted and targeted NPs along with MTX was evaluated on MCF۷, ۴T۱ and L۹۲۹ cell lines. Results: The results showed that PLGA-CUR NPs were synthetized with an average encapsulation efficiency of ۶۶% with a mean size of ۱۸۶±۳.۲ nm. The drug release of curcumin from these NPs within ۷۲h was about ۵۹% in neutral medium and ۹۰% in acidic medium. Interestingly, the combined treatment with PLGA-CUR-Apt and MTX inhibited the cancer cell's proliferation significantly more than the non-targeted nanoparticles, CUR and MTX-treated group alone. Conclusion: These results suggest that targeted PLGA-CUR nanoparticles may consider as a potential therapeutic contender in improving the efficacy of MTX in Breast cancer therapy.

نویسندگان

Maryam Hashemi

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Zahra Haghgoo

School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Rezvan Yazdian-Robati

Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Sanaz Shahgordi

Department of Immunology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Zahra Salmasi

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Khalil Abnous

Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1.Ahmadpour S, Hosseinimehr SJ. Recent developments in peptide-based SPECT radiopharmaceuticals ...
  • 2.Nagpal M, Sood S. Role of curcumin in systemic and ...
  • 3.Sa G, Das T. Anti cancer effects of curcumin: cycle ...
  • 4.Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM, ...
  • 5.Jung Y, Xu W, Kim H, Ha N, Neckers L. ...
  • 6.Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic ...
  • 7.Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, ...
  • 8.Shao ZM, Shen ZZ, Liu CH, Sartippour MR, Go VL, ...
  • 9.Shaikh J, Ankola D, Beniwal V, Singh D, Kumar MR. ...
  • 10.Song Z, Feng R, Sun M, Guo C, Gao Y, ...
  • 11.Verderio P, Bonetti P, Colombo M, Pandolfi L, Prosperi D. ...
  • 12.Kurosaki T, Higuchi N, Kawakami S, Higuchi Y, Nakamura T, ...
  • 13.Patil P, Chaudhari P, Sahu M, Duragkar N. Review article ...
  • 14.Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in ...
  • 15.Yazdian-Robati R, Ramezani M, Khedri M, Ansari N, Abnous K, ...
  • 16.Ansari N, Ghazvini K, Ramezani M, Shahdordizadeh M, Yazdian-Robati R, ...
  • 17.Bayat P, Taghdisi SM, Rafatpanah H, Abnous K, Ramezani M. ...
  • 18.Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, ...
  • 19.Hashemi M, Shamshiri A, Saeedi M, Tayebi L, Yazdian-Robati R. ...
  • 20.Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’toole MG, ...
  • 21.Yazdian-Robati R, Bayat P, Oroojalian F, Zargari M, Ramezani M, ...
  • 22.Shahgordi S, Sankian M, Yazdani Y, Mashayekhi K, Ayati SH, ...
  • 23.Ebrahimian M, Taghavi S, Mokhtarzadeh A, Ramezani M, Hashemi M. ...
  • 24.D’Souza S. A review of in vitro drug release test ...
  • 25.Yu B, Pu Y, Liu J, Liao J, Chen K, ...
  • 26.Serova M, Bieche I, Sablin M, Pronk G, Vidaud M, ...
  • 27.Chou T-C. Theoretical basis, experimental design, and computerized simulation of ...
  • 28.Rejhova A, Opattova A, Čumová A, Slíva D, Vodička P. ...
  • 29.Jin H, Qiao F, Wang Y, Xu Y, Shang Y. ...
  • 30.Banerjee S, Singh SK, Chowdhury I, Lillard Jr JW, Singh ...
  • 31.Xu X, Qin J, Liu W. Curcumin inhibits the invasion ...
  • 32.Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, ...
  • 33.Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. ...
  • 34.Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, ...
  • 35.Irving GR, Iwuji CO, Morgan B, Berry DP, Steward WP, ...
  • 36.Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP. ...
  • 37.Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, ...
  • 38.Guorgui J, Wang R, Mattheolabakis G, Mackenzie GG. Curcumin formulated ...
  • 39.Mujokoro B, Madani F, Esnaashari SS, Khosravani M, Adabi M. ...
  • 40.Nguyen HT, Dai Phung C, Thapa RK, Pham TT, Tran ...
  • 41.Hashemi M, Ebrahimian M. Recent advances in nanoformulations for co-delivery ...
  • 42.Saleh T, Soudi T, Shojaosadati SA. Aptamer functionalized curcumin-loaded human ...
  • 43.Ma Q, Qian W, Tao W, Zhou Y, Xue B. ...
  • 44.Mosafer J, Teymouri M, Abnous K, Tafaghodi M, Ramezani M. ...
  • 45.Hafezi Ghahestani Z, Alebooye Langroodi F, Mokhtarzadeh A, Ramezani M, ...
  • 46.Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin ...
  • 47.Yazdian-Robati R, Ramezani M, Jalalian SH, Abnous K, Taghdisi SM. ...
  • 48.Taghdisi SM, Danesh NM, Ramezani M, Yazdian-Robati R, Abnous K. ...
  • 49.Abnous K, Danesh NM, Ramezani M, Lavaee P, Jalalian SH, ...
  • 50.Kardani A, Yaghoobi H, Alibakhshi A, Khatami M. Inhibition of ...
  • 51.Guo J, Gao X, Su L, Xia H, Gu G, ...
  • 52.Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, ...
  • 53.Yoo HS, Lee KH, Oh JE, Park TG. In vitro ...
  • 54.Xu G, Yu X, Zhang J, Sheng Y, Liu G, ...
  • 55.Aravind A, Nair R, Raveendran S, Veeranarayanan S, Nagaoka Y, ...
  • 56.Saravanakumar K, Hu X, Shanmugam S, Chelliah R, Sekar P, ...
  • 57.Cui Y, Zhang M, Zeng F, Jin H, Xu Q, ...
  • 58.Zhou L, Duan X, Zeng S, Men K, Zhang X, ...
  • نمایش کامل مراجع